Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$117.78 USD
-0.01 (-0.01%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $117.70 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 501 - 518 ( 518 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2 EPS; Important Data Readouts from Three Ph 1 Studies Ahead, Reiterate OUTPERFORM and $41 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1 EPS; BLU-554 and BLU-285 Dose Escalations Continue, Preliminary Data Updates Expected YE:16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology AACR Roundup for Covered Companies.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Presents RET Inhibitor Program BLU-667 Data at AACR, IND Submission Expected 2H:16, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BPMC and Roche to Collaborate on Targeting Kinases in Immuno-Oncology
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q4:15 EPS, BLU-285 Enters Second Ph 1 Study, Data-Rich 2016 Ahead, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
3Q EPS: Systemic Mastocytosis Study Set to Initiate, New Preclinical Programs Revealed, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2:EPS; Multiple Studies on Track for Initiation in 2015
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1:EPS; Looking to Mid:15 IND Submissions for Lead Product Candidates BLU-285 and BLU-554
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $41 Price Target; A Template for Targeted Therapies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D